Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 10/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164033 | 0.91 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL20175968 | 0.82 | PDE2A (0.37) | ALDH1A1PDE2APKMCYP3A4CYP2C9 | |
| SCHEMBL20175962 | 0.82 | PDE2A (0.37) | ALDH1A1PDE2APKMCYP3A4CYP2C9 | |
| SCHEMBL20164026 | 0.80 | ADORA3 (0.43) | ALDH1A1PDE2AKMT2AADORA3USP2 | |
| SCHEMBL20175964 | 0.79 | PDE2A (0.46) | PDE2ACYP2C9CYP2C19ADORA3 | |
| SCHEMBL20175957 | 0.78 | PDE2A (0.50) | PDE2A | |
| SCHEMBL18362216 | 0.76 | PDE2A (0.51) | ALDH1A1PDE2A | |
| SCHEMBL20164051 | 0.74 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL20164024 | 0.74 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL20175952 | 0.63 | PDE2A (0.76) | ALDH1A1PDE2ACYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | ALDH1A1 762/4885PDE2A 1/4885PKM 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.